Tasly Pharmaceutical Group Co Ltd (600535 SHG) stock market data APIs
¥16.0609
-0.24(-1.5%)
as of July 4, 2025
Try our APIs with
free plan!
Tasly Pharmaceutical Group Co Ltd Financial Data Overview
Price chart is built with
Anychart
Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.
Prev. Close
16.0609
Open
15.8213
High
16.1777
Low
15.8702
52 wk Range
12.38-17.77
Market Cap
23 799 M
P/E Ratio
24.5077
Shares Outstanding
1 494 M
Revenue
8 504 M
EPS
0.21
Beta
0.439
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tasly Pharmaceutical Group Co Ltd data using free add-ons & libraries
Get Tasly Pharmaceutical Group Co Ltd Fundamental Data
Tasly Pharmaceutical Group Co Ltd Fundamental data includes:
- Net Revenue: 8 504 M
- EBITDA: 1 749 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tasly Pharmaceutical Group Co Ltd News
New
A chronographic analysis of MSC's rollercoasting journey
TIANJIN, China, March 18, 2025 /PRNewswire/ -- On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipo...
The debate on MSCs is over; it's time to promote MSC therapy in practice
TIANJIN, China, Feb. 26, 2025 /CNW/ -- The debate on MSCs, mesenchymal stromal cells versus mesenchymal stem cells, continued for more than two decades (since 2006), being the major obstacle for MSCs ...
Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China
- Tasly obtains exclusive development and commercialization rights for STRO-002 for Greater China - - License includes a $40 million upfront payment to Sutro, and potentially up to $345 million in de...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
